SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH H impact

QNRX Receives FDA Approval

Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome

QNRX

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.